Targovax has received very positive results regarding the survival rate of patients with pancreatic cancer.
Immune-oncology aims to help the body’s own immune system fight cancer and the ambition is to address the unmet need for long-term survival for patients with advanced cancers.
13 of 13
The company specializes in immune-oncology and is a member of Oslo Cancer Cluster. It recently released information revealing that 13 of 13 test subjects where alive after one year of treatment in a stage two clinical trial study. In addition, an active immune response–meaning the immune system was triggered to attack the cancer–was observed in as much as 11 of 13 patients.
No allergic reactions
These results came after the number of test subjects were reduced from 19 to 13 to see if allergic reactions stalled with reduced dosages of the TG01; Targovax’s lead RAS immunotherapy product. And luckily, no serious allergic reactions were observed,
Magnus Jäderberg MD, Chief Medical Officer of Targovax, said:
– We are delighted that we maintain a strong immune response and one-year survival rate with the reduced dosing regimen, essentially equivalent to and consistent with the previously reported data from the main cohort.
These new results are so positive that stock market analysts DnB Markeds predict a serious stock market rise for Targovax.
Arming the patient’s immune system to fight cancer
Targovax is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.
In July, 2016 the Company listed its shares on Oslo Axess.